Intended for healthcare professionals


Insulin-like growth factor-I can be helpful towards end of life

BMJ 2001; 322 doi: (Published 17 March 2001) Cite this as: BMJ 2001;322:674
  1. Aidan Bolger (, research fellow,
  2. Wolfram Doehner, research fellow,
  3. Stefan D Anker, research associate
  1. Department of Clinical Cardiology, National Heart and Lung Institute, London SW3 6LY

    EDITOR—In their editorial Smith et al review the literature relating high circulating concentrations of insulin-like growth factor-I to the risk of developing certain malignancies.1 They warn of the dangers of the use of exogenous insulin-like growth factor-I by athletes, in whom the additional lifetime risk of developing an associated cancer may be increased. Towards the end …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription